{"id":"W2982040065","doi":"10.1016/j.jtho.2019.08.424","title":"OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Ipilimumab; Cohort; Internal medicine; Nivolumab; Discontinuation; Oncology; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002889414,0.0001613407,0.0005428407,0.0002379701,0.00004735051,0.00001265893,0.00008427538,0.0001235933,0.0004330424],"category_scores_gemma":[0.00002349651,0.0001065119,0.00006659902,0.0002337248,0.00009519519,0.0001723903,0.00001887006,0.000314826,0.000009357315],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003484147,"about_ca_system_score_gemma":0.0002376538,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003351874,"about_ca_topic_score_gemma":0.0006957463,"domain_scores_codex":[0.9987733,0.0000665485,0.0004990761,0.0001736044,0.0002580313,0.0002294557],"domain_scores_gemma":[0.998992,0.00005525842,0.0005150624,0.0001711959,0.0001692535,0.00009722849],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1184851,0.001101706,0.6706893,0.0001160586,0.0002924328,0.00009896071,0.0008141178,0.0001622593,0.0004177255,0.00001592922,0.0006418794,0.2071645],"study_design_scores_gemma":[0.02471775,0.01570011,0.9193359,0.0007285347,0.0002006251,0.0003757655,0.0003057986,0.00005594561,0.0002246023,0.00007328614,0.0380533,0.0002283646],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951262,0.0002721836,0.00003683575,0.001375858,0.0005173257,0.0004261757,0.00000867956,0.000008025374,0.002228701],"genre_scores_gemma":[0.9960281,0.0000716816,0.002500516,0.0005275242,0.0003858838,0.000004114956,0.000005367937,0.00002922949,0.0004476339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2486466,"threshold_uncertainty_score":0.474151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01503708710134724,"score_gpt":0.3432745938222109,"score_spread":0.3282375067208637,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}